Confocal endomicroscopy to predict ulcerative colitis outcomes
Part of Digestive system clinical trials.
This study uses a special microscope during a colonoscopy to look at the lining of your colon in detail. It aims to see if this microscope can help predict how ulcerative colitis will progress, which could guide treatment decisions.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have had ulcerative colitis for at least 12 weeks.
- You are 18 years or older.
- You have active symptoms (like rectal bleeding and frequent bowel movements).
- You are able to have a colonoscopy with a special microscope (no allergies to fluorescein dye or other medical reasons against it).
- You are not pregnant.
- You can understand the study and sign a consent form.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study checks biomarkers (signals in blood and/or stool) in adults with moderate-to-severe ulcerative colitis. It compares patients starting targeted medicines and looks for marker patterns that may reflect how the disease is behaving.
This trial uses a gentle ultrasound scan (on the outside of the body) to see how well treatment is working during a moderate to severe flare of ulcerative colitis. It aims to find out if this painless test can predict recovery and help guide care without needing a telescope exam (endoscopy).
This study compares different special camera techniques during colonoscopy to see which best finds early abnormal (pre-cancer) changes in people with long-term ulcerative colitis. It may help doctors improve how they screen and monitor your colon over time.
This study looks at new ways to detect scarring (fibrosis) in the bowel using advanced imaging and tests. It may help doctors better understand and monitor ulcerative colitis. If you are already having a colonoscopy, you may be able to join.
This trial tests whether “treat-to-target” care—guided by regular symptom checks, telemonitoring, and patient education—works better than standard follow-up when starting adalimumab for ulcerative colitis. It aims to help control inflammation more effectively and reduce flare-ups.
This study looks at blood and/or tissue “molecular” (cell-level) reasons why treatments don’t fully work in adults with Crohn’s disease or ulcerative colitis. If you are starting a biologic or small-molecule medicine and still have moderate to severe symptoms, you may be able to contribute to research that helps improve future care.
Hear when a new Ulcerative Colitis trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.